Skip to Content

Generic Belviq XR Availability

See also: Generic Belviq

Belviq XR is a brand name of lorcaserin, approved by the FDA in the following formulation(s):

BELVIQ XR (lorcaserin hydrochloride - tablet, extended release;oral)

  • Manufacturer: EISAI INC
    Approval date: July 15, 2016
    Strength(s): 20MG [RLD]

Has a generic version of Belviq XR been approved?

No. There is currently no therapeutically equivalent version of Belviq XR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Belviq XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 5HT2C receptor modulators
    Patent 6,953,787
    Issued: October 11, 2005
    Inventor(s): Smith; Brian & Smith; Jeffrey
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 5HT2c receptor modulators
    Patent 7,514,422
    Issued: April 7, 2009
    Inventor(s): Smith; Brian & Smith; Jeffrey
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
  • 5HT2C receptor modulators
    Patent 7,977,329
    Issued: July 12, 2011
    Inventor(s): Smith; Jeffrey & Smith; Brian
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
    Patent 8,168,624
    Issued: May 1, 2012
    Inventor(s): Agarwal; Rajesh K. & Betts, III; William L. & Henshilwood; James A. & Kiang; Yuan-Hon & Post; Noah
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same, preparations, and uses thereof.
    Patent expiration dates:
    • April 18, 2029
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 5HT2c receptor modulators
    Patent 8,207,158
    Issued: June 26, 2012
    Inventor(s): Smith; Brian & Smith; Jeffrey
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
  • 5HT2C receptor modulators
    Patent 8,273,734
    Issued: September 25, 2012
    Inventor(s): Smith; Brian & Smith; Jeffrey
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
  • Processes for preparing 3-benzazepines
    Patent 8,367,657
    Issued: February 5, 2013
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 5HT2C receptor modulators
    Patent 8,546,379
    Issued: October 1, 2013
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 5HT2C receptor modulators
    Patent 8,575,149
    Issued: November 5, 2013
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Patent expiration dates:
    • April 10, 2023
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT
  • Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride
    Patent 8,697,686
    Issued: April 15, 2014
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same and uses thereof.
    Patent expiration dates:
    • December 20, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Processes for preparing 3-benzazepines
    Patent 8,946,207
    Issued: February 3, 2015
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Patent expiration dates:
    • June 16, 2024
      ✓ 
      Drug product
  • Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
    Patent 8,980,881
    Issued: March 17, 2015
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same and uses thereof.
    Patent expiration dates:
    • December 20, 2025
      ✓ 
      Patent use: METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
    • December 20, 2025
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
    • December 20, 2025
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
    • December 20, 2025
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
  • Administration of an anti-obesity compound to individuals with renal impairment
    Patent 8,999,970
    Issued: April 7, 2015
    Assignee(s): Arena Pharmaceuticals, Inc.
    The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.
    Patent expiration dates:
    • February 7, 2033
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
    • February 7, 2033
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
    • February 7, 2033
      ✓ 
      Patent use: METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
  • Method of weight management
    Patent 9,169,213
    Issued: October 27, 2015
    Assignee(s): Arena Pharmaceuticals, Inc.
    Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
    Patent expiration dates:
    • December 6, 2032
    • December 6, 2032
    • December 6, 2032
    • December 6, 2032

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 27, 2017 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide